Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

Stopped early · Early Phase 1

Conditions studied: Glioma, Brain Neoplasms, Brain Metastasis

In brief

This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant gliomas or metastatic brain cancer. This study will also determine the toxicity and tolerability of a phosphodiesterase-V inhibitor (vardenafil) in combination with intravenous carboplatin for patients with recurrent malignant gliomas or metastatic brain cancer.

Key facts

Study ID

NCT02279992

Run by

Cedars-Sinai Medical Center

People needed

7

Starts

2012-03-27

Expected to finish

2016-02-11

Last updated by the study team

2017-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with recurrent malignant glioma or metastatic brain cancer requiring craniotomy for gross total resection, subtotal resection or biopsy
• Previously histopathologically proven glioma or radiographic appearance of metastatic lesion with a primary neoplasm that is known to metastasize to the brain
• Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
• Patients must have normal hematologic, renal and liver function (i.e. Hemoglobin >10 gm/dl, Absolute neutrophil count ≥ 1500/mm3, Platelets ≥ 100,000/mm3, creatinine ≤ 1.5 mg/dl or Cr Clearance ≥ 60 mL/min, total bilirubin ≤ 1.5 mg/dl, transaminases ≤ 4 times above the upper limits of the institutional normal.
• Patients must be able to provide written informed consent

You may not qualify if…

• Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety
• Patients who are pregnant or breast-feeding
• Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
• Allergy to 5HT-(3) receptor antagonist including tropisetron, ondansetron
• Patients on enzyme-inducing anticonvulsants (Dilantin, Tegretol, Phenobarbital)
• Patients with unstable angina or serious cardiovascular disease
• Known HIV positivity or AIDS-related illness
• History of allergic reaction to platinum compounds or mannitol
• Medical conditions requiring the use of oral nitrates
• Patients on alpha-1 adrenergic blockers

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.